Cargando…

Immunological features of coronavirus disease 2019 in patients with cancer

BACKGROUND: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2, has caused a major pandemic. Patients with cancer are at higher risk of severe COVID-19. We aimed to describe and compare the immunological features of cancer patients hospitalised for COVID-1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thibaudin, Marion, Fumet, Jean-David, Bon, Marjorie, Hampe, Léa, Limagne, Emeric, Ghiringhelli, Francois
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Ltd. 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476569/ https://www.ncbi.nlm.nih.gov/pubmed/32977223 http://dx.doi.org/10.1016/j.ejca.2020.08.013

Ejemplares similares

Immunogenic Cell Death and Elimination of Immunosuppressive Cells: A Double-Edged Sword of Chemotherapy
por: Fumet, Jean-David, et al.
Publicado: (2020)

Protocol for simultaneous analysis of peripheral and intratumoral lymphocyte function by flow cytometry
por: Daumoine, Susy, et al.
Publicado: (2023)

Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment
por: Fumet, Jean-David, et al.
Publicado: (2020)

Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients
por: Limagne, Emeric, et al.
Publicado: (2019)

Evaluation of tumor immune contexture among intrinsic molecular subtypes helps to predict outcome in early breast cancer
por: Klopfenstein, Quentin, et al.
Publicado: (2021)

Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination
por: Grapin, Mathieu, et al.
Publicado: (2019)

First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial
por: Thibaudin, Marion, et al.
Publicado: (2023)

Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1/PD-L1 immune checkpoint blockers
por: Medjebar, Soleine, et al.
Publicado: (2020)

Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
por: Derangère, Valentin, et al.
Publicado: (2016)

Chemoimmunotherapy triggers immune responses targeting microsatellite stable colorectal cancer
por: Thibaudin, Marion, et al.
Publicado: (2023)

Lysophosphatidylcholine acyltransferase 2-mediated lipid droplet production supports colorectal cancer chemoresistance
por: Cotte, Alexia Karen, et al.
Publicado: (2018)

Is There a Place for Immunotherapy for Metastatic Microsatellite Stable Colorectal Cancer?
por: Ghiringhelli, François, et al.
Publicado: (2019)

IRF8-dependent molecular complexes control the Th9 transcriptional program
por: Humblin, Etienne, et al.
Publicado: (2017)

Targeting BRAF and RAS in Colorectal Cancer
por: Bellio, Helene, et al.
Publicado: (2021)

A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer
por: Roussot, Nicolas, et al.
Publicado: (2023)

Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era
por: Kalfeist, Laura, et al.
Publicado: (2022)

Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness
por: Barnestein, Robby, et al.
Publicado: (2022)

Simultaneous isolation of CD45 tumor-infiltrating lymphocytes, tumor cells, and associated fibroblasts from murine breast tumor model by MACS
por: Kalfeist, Laura, et al.
Publicado: (2023)

Sex- and age-specific clinical and immunological features of coronavirus disease 2019
por: Jin, Shengwei, et al.
Publicado: (2021)

Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer
por: Fumet, Jean-David, et al.
Publicado: (2018)

Immunologic Features in Coronavirus Disease 2019: Functional Exhaustion of T Cells and Cytokine Storm
por: Mahmoudi, Shima, et al.
Publicado: (2020)

Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal Carcinoma
por: Niogret, Julie, et al.
Publicado: (2020)

Capillary density has no value as an early biomarker of bevacizumab efficacy in metastatic colorectal cancers: a prospective clinical trial
por: Fumet, Jean-David, et al.
Publicado: (2017)

Impact of proton therapy on antitumor immune response
por: Mirjolet, Céline, et al.
Publicado: (2021)

Follicular helper-T cells restore CD8(+)-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy
por: Niogret, Julie, et al.
Publicado: (2021)

Fluorouracil and bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): a single-arm phase 2 study
por: Isambert, Nicolas, et al.
Publicado: (2018)

Haematological and immunological data of Chinese children infected with coronavirus disease 2019
por: Xiong, Xiaoli, et al.
Publicado: (2020)

Coronavirus disease 2019 and pityriasis rosea: A review of the immunological connection
por: Borgia, Francesco, et al.
Publicado: (2022)

Therapeutic Associations Comprising Anti-PD-1/PD-L1 in Breast Cancer: Clinical Challenges and Perspectives
por: Ledys, Fanny, et al.
Publicado: (2021)

Coronavirus disease 2019 (COVID-19): Immunological approaches and emerging pharmacologic treatments
por: Goodarzi, Pedram, et al.
Publicado: (2020)

US public health resources for coronavirus disease 2019 that are relevant to allergy-immunology
por: Hsu, Joy
Publicado: (2021)

Immunologic aspects of characteristics, diagnosis, and treatment of coronavirus disease 2019 (COVID-19)
por: Chang, Feng-Yee, et al.
Publicado: (2020)

The Clinical Presentation and Immunology of Viral Pneumonia and Implications for Management of Coronavirus Disease 2019
por: Darden, Dijoia B., et al.
Publicado: (2020)

The Dynamic Immunological Parameter Landscape in Coronavirus Disease 2019 Patients With Different Outcomes
por: Tang, Guoxing, et al.
Publicado: (2021)

Commentary: Evolving understanding of coronavirus disease 2019: Molecular biology, immunology, and surgery
por: Buratto, Edward, et al.
Publicado: (2021)

Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses
por: Raoult, Didier, et al.
Publicado: (2020)

Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies
por: Oster, Paul, et al.
Publicado: (2022)

Immunologic Characterization of Coronavirus Disease 2019 (COVID-19) Patients with Hematological Cancer: Biologic and Clinical Significance
por: Maia, Catarina, et al.
Publicado: (2020)

Epidemiology and clinical features of coronavirus disease 2019 in children
por: Choi, Soo-Han, et al.
Publicado: (2020)

Pediatric Coronavirus Disease 2019: Clinical Features and Management
por: Sahi, Puneet Kaur, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_av0r7edf2ib3gakirgeagt8tsk